Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Biostage. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Biostage's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biostage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Biostage's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Biostage's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Biostage's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Biostage is high growth as no earnings estimate data is available.
Unable to determine if Biostage is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Biostage's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. James J. McGorry, also known as Jim, has been the Chief Executive Officer of Biostage, Inc. (formerly, Harvard Apparatus Regenerative Technology, Inc) since July 6, 2015 and served as its President from July 6, 2015 to March 16, 2017. Mr. McGorry served as an Executive Officer of Genzyme Surgical Products. Mr. McGorry is a seasoned life science executive with over twenty-five years of leadership experience in both medical technology and biotechnology businesses. He served as an Executive Vice President of Sales and Marketing at Accellent, Inc. from August 29, 2011 to December 31, 2012. He was responsible for commercial operations resulting in global expansion, product extensions and profitable growth. From 1985 to 1996, he had been with American Hospital Supply Corporation including served as its Vice President of Corporate Sales, Southern Region. He has significant executive leadership, operating and management experience in and knowledge of the life sciences, medical technology and biotechnology industries. Mr. McGorry served an Executive Vice President and General Manager of The Translational Oncology Solutions Business at Champions Oncology, Inc. from September 3, 2013 to July 2, 2015. He served as a Senior Vice President of Oncology and Transplant at Genzyme, where he served for 12 years and was responsible for establishing and executing the commercial development, product general management and global expansion of Genzyme's Oncology franchise in 90 countries. He served as Senior Vice President of Oncology at Genzyme Corporation from 2003 to 2010. From 1998 to 2003, he served other senior level positions within Genzyme including Senior Vice President, General Manager, Cardiac Devices and Senior Vice President, General Manager, Bio-Surgical Specialties. Mr. McGorry spent over ten years with Baxter Healthcare. He served in the United States Military from 1979 to 1985. He has been a Director of ISTO Technologies, Inc. since January 2014. Mr. McGorry has been a Director of Biostage, Inc. since February 25, 2013. He serves as a Director of Harvard Apparatus Regenerative Medicine. Mr. McGorry holds an MBA from Duke University Fuqua School of Business and a B.A. from the United States Military Academy at West Point.
Jim's compensation has been consistent with company performance over the past year.
Jim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Biostage management team is about average.
CEO & Director
CFO & Secretary
Director of Quality & Operations
Chief Scientific Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Biostage board of directors is less than 3 years, this suggests a new board.
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company’s Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.